Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc. (NYSE: GMED) is a leading designer and developer of innovative spinal implants and related surgical solutions. Founded in 2003 and headquartered in Audubon, Pennsylvania, the company has built its reputation on advancing the standard of care in spine surgery through a broad portfolio of implant systems, biologics, and specialized surgical instruments. Early collaborations with prominent surgeons helped Globus Medical introduce technologies that streamline procedures, reduce operative time, and improve clinical outcomes.

The company’s product offerings encompass a wide range of spinal implant systems, including interbody fusion devices, posterior fixation systems, and minimally invasive surgical platforms. Globus Medical also offers a suite of biologic materials designed to support bone healing and fusion, alongside navigation and robotic-assisted surgery solutions that enable precise implant placement. By integrating its proprietary technology with digital planning and intraoperative guidance tools, the company supports surgeons in delivering consistent, reproducible results for patients suffering from degenerative spinal conditions, trauma, deformity, and other spinal pathologies.

Globus Medical operates globally, serving hospitals, surgical centers, and physician practices across North America, Europe, Asia-Pacific, and Latin America. The company maintains a network of direct sales offices and distributor relationships to ensure timely product availability and responsive clinical support. Ongoing investments in research and development centers in the United States and abroad underscore its commitment to expanding clinical indications, refining surgical workflows, and launching new platforms tailored to regional market needs.

Under the leadership of founder and CEO David Demski, Globus Medical emphasizes a collaborative culture that brings together engineers, surgeons, and healthcare professionals. The executive team’s deep expertise in biomedical engineering, regulatory affairs, and global operations has guided the company’s growth from a start-up to a publicly traded medical device firm. With a focus on innovation, quality manufacturing, and evidence-based performance, Globus Medical continues to pursue strategic partnerships and clinical studies aimed at transforming spine care worldwide.

Key Stats

• Today's Range: $56.98 to $58.44
• 50-Day Range: $55.54 to $72.46
• 52-Week Range: $54.48 to $94.93
• Volume: 972,599 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $7.82 billion
• P/E Ratio: 43.10
• Dividend Yield: N/A
• Price Target: $94.00
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 99% of companies evaluated by MarketBeat, and ranked 20th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Globus Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 17.15%

Earnings Growth

Earnings for Globus Medical are expected to grow by 17.15% in the coming year, from $3.44 to $4.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 43.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 43.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.21% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently decreased by 10.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

4.21% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently decreased by 10.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.58

News Sentiment

Globus Medical has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Globus Medical this week, compared to 11 articles on an average week.

Search Interest

Only 4 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

3 people have added Globus Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.51% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GMED Stock Analysis - Frequently Asked Questions

How have GMED shares performed this year?

Globus Medical's stock was trading at $82.71 at the start of the year. Since then, GMED shares have decreased by 30.2% and is now trading at $57.76.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) released its quarterly earnings data on Thursday, May, 8th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.74 by $0.06. The business's revenue was down 1.4% on a year-over-year basis.
Read the conference call transcript.

Is Globus Medical buying back stock?

Globus Medical's board approved a stock buyback plan on Thursday, May 15th 2025, which authorizes the company to repurchase $500,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its shares are undervalued.

Who are Globus Medical's major shareholders?

Top institutional shareholders of Globus Medical include Swedbank AB (0.46%), Exchange Traded Concepts LLC (0.16%), TT International Asset Management LTD (0.04%) and Radnor Capital Management LLC (0.02%). Insiders that own company stock include David D Davidar, Ann D Rhoads, Leslie V Norwalk, Daniel T Scavilla, Dan Lemaitre, Keith W Pfeil and Kelly Huller.
View institutional ownership trends.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 5,300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Globus Medical: $94.00
• High Price Target: $115.00
• Low Price Target: $68.00
• Potential Upside/Downside: +62.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.34
• Trailing P/E Ratio: 43.10
• Forward P/E Ratio: 16.79
• P/E Growth: 1.67
• Net Income: $102.98 million
• Net Margins: 7.39%
• Pretax Margin: 9.28%
• Return on Equity: 10.52%
• Return on Assets: 8.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.45
• Quick Ratio: 2.72

Sales & Book Value

• Annual Sales: $2.52 billion
• Price / Sales: 3.10
• Cash Flow: $6.71 per share
• Price / Cash Flow: 8.61
• Book Value: $30.40 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 135,380,000
• Free Float: 110,320,000
• Market Cap: $7.82 billion
• Optionable: Optionable
• Beta: 1.19